1. Are New Science and Precision Medicine linked?

New Science and Precision Medicine are closely linked. New Science is a dynamic combination of the best in science and health technology that is projected to drive 61 percent of biopharma revenues until 2026, representing 81% of anticipated industry revenue growth. Precision Medicine has grown with the mapping of the genome to drive the development of personalized treatments for individuals or patient populations. Both work in combination with new, analytical scientific and technological advances to positively impact the biopharma business and help deliver better health outcomes. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care. Accelerated development in cell and gene therapies (CGT) is causing a fundamental shift in the traditional biopharmaceutical business model. Both represent a medical revolution.

2. Why is oncology emphasized over other TAs?

New Science is driving exceptional growth across multiple therapeutic areas, but primarily in oncology. The one-size-fits-all cancer treatment approach has been replaced by personalized precision medicine. Standard cancer therapies are ineffective in over 75% of patients. One of the highest therapy failure rates for all diseases. Precision oncology is designed to change that.

3. What is cell and gene therapy used for?

One of the most exciting areas of innovation in medicine today is in the Cell and Gene Therapy (CGT) sector, with many therapies already changing the industry and patients’ lives. CGT is increasingly being viewed as a superior therapy for life-threatening illnesses such as cancer—and in a growing number of indications, it is being used as a first-line therapeutic approach with the potential to cure diseases entirely. While the science that supports CGT is complex, in the simplest of terms, CGT treats the underlying causes of disease by modifying an individual’s cells and/or genes, typically externally, and re-introducing them to the patient to treat the disease.

4. Does INTIENT support cell and gene therapy?

As demand for cell and gene therapies increases so does the demand for clinical trials. Industry leaders are focused on technology innovations, but struggle to find a holistic solution. While off-the-shelf digital solutions exist, they are typically focused on fragments of the overall process. As a result, they resort to the creation of bespoke solutions that create redundancies in the system. INTIENT Unify Cell & Gene connects stakeholders across the value chain, enabling manufacturers, supply chain partners and Healthcare Providers (HCPs) to work in a harmonized, standardized way.

Precision Medicine

Our comprehensive survey of 1800 people in the US

Health and Life Sciences Experience Survey 2021

Our cell and gene expertise

Working with clients in all three commercially approved CGT therapies.

Active clients in CGT globally.

We are helping clients across three areas: R&D, supply chain and patient engagement.

CAR-T cell therapy: Meet Emily Whitehead

Together through data collaboratives

INTIENT Unify

Enabling next-gen Cell & Gene Therapies

The potential of precision medicine

$2M

For the most expensive precision medicine today.¹

700

New cancer drugs are currently in late-stage development, and over 90% of these are targeted therapies.²

67%

Increase in the number of active agents in the global immuno-oncology pipeline.³

What we do

Growth services

Bringing our deep precision medicine expertise to help clients design and build drug development for shifting manufacturing and commercial operations.

Experience and service strategy and design

Shaping and designing industry-leading patient and healthcare professional experiences and services with our business service design arm Fjord.

Advanced analytics

Leveraging our data science expertise: accelerate R&D, enable clinically relevant biomarkers, action patient care analytics along their lifespan.

Data and platform strategies

Aggregating, analyzing and actioning patient data and insight from across their healthcare and everyday experience using architectures and platforms, including INTIENT.

Accelerating the culture cure

Advancements in cell and gene therapy

What we think

VIEW MORE ARTICLES

Precision Medicine

The experience report – Cancer patient issue

The Cancer Patient Issue takes a human-centered approach—this time to uncover the main pain points for cancer patients.

New Science

Biopharma’s golden opportunity

A differentiated engagement is about understanding the needs of oncologists to better support them and doing so offers significant value to biopharma.